VANCOUVER, BC / ACCESSWIRE / September 27, 2023 / EvokAI Creative Labs Inc. (TSXV:OKAI)(OTCQB:OKAIF) ("EvokAI" or the "Company"), a leading MedTech AI-powered company dedicated to the development of transformational and innovative technologies for the healthcare sector, is pleased to announce the commencement of the CE Mark certification process for its groundbreaking technology "MDM Flex Sensor" designed to transform the management of Parkinson's disease and related movement disorders.

"Parkinson's disease is a complex neurodegenerative disorder affecting millions worldwide, the initiation of the CE Mark certification is a significant step towards making the MDM Flex Sensor available to patients in Europe and beyond. The development of our cutting-edge technology in collaboration with one of the most prestigious research institutions in the world, VTT Technical Research Centre of Finland, underscores our commitment to excellence and innovation. This partnership has provided us with access to world-class expertise, state-of-the-art facilities, and a collaborative environment that fosters groundbreaking discoveries," said Alejandro Antalich, CEO of EvokAI.

Key Highlights of EvokAI's MDM Flex Sensor:

1. Innovative Approach: EvokAI's technology represents a paradigm shift in the management of Parkinson's disease. It leverages state-of-the-art advancements in medical technology to provide more effective and personalized care.
   
2. Enhanced Patient Outcomes: The technology is designed to improve the quality of life for individuals living with Parkinson's disease. It aims to address challenges such as monitoring the level and frequency of the tremors 24/7, ultimately offering greater independence and well-being.
   
3. Personalized Care: EvokAI's solution takes a patient-centric approach by tailoring treatment plans to the unique needs of each individual. This personalization allows for optimized symptom control and medication adjustments, leading to improved outcomes.
   
4. Remote Monitoring: The technology includes remote monitoring capabilities, enabling healthcare professionals to closely track patients' progress and make timely adjustments to their treatment plans. This is especially valuable in the current era of telemedicine.
   
5. Clinical Validation: EvokAI has conducted rigorous clinical trials and studies to validate the safety and efficacy of its Parkinson's technology. The initiation of the CE Mark certification process underscores the Company's confidence in the technology's potential.
   
6. Global Impact: Upon CE Mark certification, EvokAI plans to make its Parkinson's technology available to patients across Europe. This represents a significant step towards addressing the unmet medical needs of the Parkinson's community on a global scale.

"We anticipate the completion of testing and certification by the fourth quarter of 2023. The MDM Flex Sensor is set to bring substantial improvements to the EvokAI's Movement Disorder Monitor ("MDM"). The MDM is a groundbreaking innovation designed to revolutionize the early detection and treatment of movement disorders, ultimately enhancing the quality of life for individuals affected by these conditions. The integration of the MDM Flex Sensor into EvokAI's MDM will enable unparalleled accuracy in monitoring and analyzing subtle movements and tremors, which are often early indicators of movement disorders such as Parkinson's disease. This enhancement will empower healthcare professionals with a powerful tool for early diagnosis, intervention and tailored treatment strategies," commented Dr. Georg Meissner, Executive Vice President, Digital Health Research & Technology of EvokAI.

About EvokAI Creative Labs Inc.
EvokAI is a MedTech AI-powered company dedicated to the development of transformational and innovative technologies for the modern healthcare sector. We deploy machine learning models to search medical data and uncover insights to help improve health outcomes, patient experiences, drug development, preclinical and clinical decisions and provide more accurate diagnoses. EvokAI tailors its AI algorithms across the whole healthcare system, from hospitals, private clinics, research institutions, pharmaceutical companies, contract research organizations, to medical professionals, patients, healthy individuals aiming at preventing any kind of disease and beyond, protecting the aging genome.

On behalf of the Board of Directors of EvokAI Creative Labs Inc.

Alejandro Antalich
CEO & Director

For more information, please contact:
EvokAI Creative Labs Inc.
Alejandro Antalich
Chief Executive Officer
Email: hello@evokailabs.com
Phone: +358 50 5512 848

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Generally, any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information or statements.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: business integration risks; fluctuations in general macroeconomic conditions; fluctuations in securities markets; the Company's limited operating history; future capital needs and uncertainty of additional financing; the competitive nature of the technology industry; unproven markets for the Company's product offerings; lack of regulation and customer protection; the need for the Company to manage its planned growth and expansion; the effects of product development and need for continued technology change; protection of proprietary rights; network security risks; the ability of the Company to maintain properly working systems; foreign currency trading risks; use and storage of personal information and compliance with privacy laws; use of the Company's services for improper or illegal purposes; global economic and financial market conditions; uninsurable risks; changes in project parameters as plans continue to be evaluated; and those factors described under the heading "Risks Factors" in the Company's filing statement dated March 27, 2023 available on SEDAR. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking statements and information. There can be no assurance that forward-looking information, or the material factors or assumptions used to develop such forward-looking information, will prove to be accurate. The Company does not undertake any obligations to release publicly any revisions for updating any voluntary forward-looking statements, except as required by applicable securities law.

SOURCE: EvokAI Creative Labs Inc.